Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 20 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Benitec Biopharma Limited | BNTC | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 6.72 | 04:24:21 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 6.72 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 1 | 20 | - | 1.86 - 9.01 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 04:00:20 | 20 | $ 6.70 | USD |
Benitec Biopharma Limited Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 17.42M | - | - | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Benitec Biopharma News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BNTC Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 4.88 | 7.42 | 4.75 | 6.81 | 785,402 | 1.84 | 37.70% |
| 1 Month | 4.98 | 7.42 | 4.75 | 6.72 | 222,679 | 1.74 | 34.94% |
| 3 Months | 3.04 | 7.42 | 2.70 | 6.37 | 85,991 | 3.68 | 121.05% |
| 6 Months | 3.07 | 7.42 | 2.69 | 6.03 | 44,718 | 3.65 | 118.89% |
| 1 Year | 3.7757 | 9.01 | 1.86 | 5.41 | 1,050,352 | 2.94 | 77.98% |
| 3 Years | 84.15 | 99.62 | 1.86 | 14.33 | 684,507 | -77.43 | -92.01% |
| 5 Years | 29.92 | 295.6198 | 1.86 | 46.39 | 581,408 | -23.20 | -77.54% |
Benitec Biopharma Description
| Benitec Biopharma Inc is a biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference with gene therapy for providing sustained, long-lasting silencing of disease-causing genes from a single administration. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The company is developing product candidates in chronic and life-threatening human disease areas including Orphan disease: Oculopharyngeal Muscular Dystrophy (OPMD) and Infectious disease: Hepatitis B Virus (HBV). |
